semaglutide type 1 diabetes trial in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical New Science Suggests Semaglutide Improves

[3] Pre-injection preparation also matters

[WEGOVY CTA] What Is the Wegovy Pen

2014 Mar;144(3):252-7

In a detailed follow-up analysis of SELECT, researchers found: People got similar cardiovascular protection whether they: lost 5% of body weight, or lost very little weight (or even none) Thats a major finding because it suggests semaglutide may protect the heart through multiple pathways, such as: lowering inflammation improving blood vessel function reducing blood pressure improving cholesterol and lipid markers In SELECT, semaglutide also improved several risk indicators, including lower blood pressure and a major drop in C-reactive protein (CRP) a marker linked with inflammation and heart risk